🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522111-42-02
Authorised Phase IV

Long-term muscle synthetic effects of intradialytic parenteral nutrition in chronic hemodialysis patients

2025-522111-42-02 · tracked via the Priya Life Science EU tracker
Sponsor
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Nutritional and Metabolic Diseases
Decision date
27/10/2025
Enrollment target
20
Sites
Netherlands

Condition studied

muscle protein turnover hemodialysis

Investigational medicinal product(s)

COMBINATIONS

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Difference in myofibrillar fractional synthetic rate during a one-week treatment with IDPN versus control

Endpoint detail

1. Intradialytic forearm amino acid balance, 2. difference in the loss of amino acids in the dialysate during a one-week treatment with IDPN versus control period, 3. Effects of IDPN on intradialytic blood pressure and cardiac output.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522111-42-02 on CTIS ↗ ← All trials in the EU